Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.43 |
| ▸ | WDR5 | P61964 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 5/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23877629 | 0.88 | CDK2 (0.46) | PTGS1AKR1C3AKR1C2PTGS2TAS2R14 | |
| SCHEMBL221906 | 0.80 | ACLY (0.49) | KDM4ESMN1; SMN2HSD17B10MCL1KMT2A | |
| SCHEMBL7556102 | 0.78 | ACLY (0.62) | KDM4ESMN1; SMN2HSD17B10MCL1KMT2A | |
| SCHEMBL6307782 | 0.78 | KDM4E (0.62) | AKR1C3AKR1C2KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL2365878 | 0.76 | ALDH1A1 (0.58) | AKR1C3AKR1C2KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL7556603 | 0.76 | CCR2 (0.63) | KDM4ESMN1; SMN2HSD17B10KMT2AACLY | |
| SCHEMBL31046844 | 0.76 | AKR1C3 (0.39) | PTGS1AKR1C3AKR1C2PTGS2TAS2R14 | |
| SCHEMBL23141169 | 0.76 | KDM4E (0.49) | KDM4ESMN1; SMN2HSD17B10MCL1KMT2A | |
| SCHEMBL7552232 | 0.76 | LMNA (0.54) | AKR1C3AKR1C2KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL28047975 | 0.76 | KDM4E (0.50) | KDM4ESMN1; SMN2HSD17B10MCL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118791407-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118638096-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-112204008-B | Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives | 奥索生物公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | PTGS1 2000/4885AKR1C3 3403/4885AKR1C2 2364/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | PTGS1 2000/4885AKR1C3 3403/4885AKR1C2 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.